ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2808

Role of Serum Autoantibodies in Blood Brain Barrier Damages in Neuropsychiatric Systemic Lupus Erythematosus

Shunsei Hirohata1, Yuko Sakuma2, Tamiko Yanagida3 and Taku Yoshio4, 1Kitasato University School of Medicine, Sagamihara, Japan, 2Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan, 3Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, 4Jichi Medical University, Tochigi, Japan

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: autoantibodies, neuropsychiatric disorders and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster III: Biomarkers and Nephritis

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Neuropsychiatric manifestation in systemic lupus erythematosus (NPSLE) is one of the most serious complications of the disease. We have recently demonstrated that the breakdown of blood brain barrier (BBB) plays a crucial role in the development of diffuse psychiatric/neuropsychological manifestations (diffuse NPSLE), allowing influx of neuron-reactive autoantibodies from systemic circulation into the brain. However, the mechanism of BBB damages remains unclear. Of note, various autoantibodies have been implicated in the pathogenesis in NPSLE. The present study was designed in order to elucidate the roles of serum autoantibodies in the development of BBB damages In NPSLE.

Methods: Paired serum and cerebrospinal fluid (CSF) samples were obtained from 101 SLE patients when they presented active neuropsychiatric manifestations (69 patients with diffuse psychiatric/neuropsychological syndromes [diffuse NPSLE] and 32 patients with neurologic syndromes or peripheral nervous system involvement [focal NPSLE]). IgG anti-NR2 subunit of NMDA receptor (anti-NR2), anti-Sm, anti-RNP and anti-ribosomal P (anti-P) in sera and albumin in CSF and sera were measured by ELISA.

Results: Q albumin (CSF/serum albumin quotient) was significantly higher in acute confusional state (ACS) than in non-ACS diffuse NPSLE (anxiety disorder, cognitive dysfunction, mood disorder and psychosis) or in focal NPSLE. Serum anti-Sm, but not anti-RNP, anti-NR2 or anti-P, was significantly elevated in ACS compared with the other 2 groups of NPSLE. Accordingly, only serum anti-Sm (r=0.2655, p=0.0073), but not anti-RNP (r=0.0551), anti-NR2 (r=0.0817) or anti-P (r=0.1280), was significantly correlated with Q albumin.

Conclusion: These results confirm that the severity of BBB damages plays a crucial role in the development of ACS, the severest form of diffuse NPSLE. Moreover, the data indicate that serum anti-Sm might play a most important role in BBB breakdown in NPSLE.


Disclosure: S. Hirohata, None; Y. Sakuma, None; T. Yanagida, None; T. Yoshio, None.

To cite this abstract in AMA style:

Hirohata S, Sakuma Y, Yanagida T, Yoshio T. Role of Serum Autoantibodies in Blood Brain Barrier Damages in Neuropsychiatric Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/role-of-serum-autoantibodies-in-blood-brain-barrier-damages-in-neuropsychiatric-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/role-of-serum-autoantibodies-in-blood-brain-barrier-damages-in-neuropsychiatric-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology